Acadian Asset Management
CBIO

Acadian Asset Management’s Crescent Biopharma CBIO Stock Holding History

Acadian Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11
Closed – – 1697
2024
Q4 		$0 Sell
11
-3,563
-100% -$97.1K ﹤0.01% 1833
2024
Q3 		$59K Sell
3,574
-1,774
-33% -$37.2K ﹤0.01% 1749
2024
Q2 		$150K Buy
5,348
+2,043
+62% +$212K ﹤0.01% 1480
2024
Q1 		$991K Sell
3,305
-2,107
-39% -$629K ﹤0.01% 842
2023
Q4 		$1.27M Sell
5,412
-3,029
-36% -$471K ﹤0.01% 791
2023
Q3 		$1.26M Sell
8,441
-3,056
-27% -$482K 0.01% 808
2023
Q2 		$2M Sell
11,497
-2,520
-18% -$423K 0.01% 688
2023
Q1 		$1.76M Sell
14,017
-5,414
-28% -$1.22M 0.01% 740
2022
Q4 		$5.89M Sell
19,431
-470
-2% -$69.3K 0.03% 401
2022
Q3 		$1.1M Hold
19,901
– – 0.01% 782
2022
Q2 		$1.19M Hold
19,901
– – 0.01% 775
2022
Q1 		$2.27M Buy
19,901
+390
+2% +$45.8K 0.01% 643
2021
Q4 		$2.81M Buy
19,511
+650
+3% +$118K 0.01% 577
2021
Q3 		$4.13M Sell
18,861
-656
-3% -$139K 0.02% 498
2021
Q2 		$4.53M Buy
19,517
+3,064
+19% +$780K 0.02% 490
2021
Q1 		$4.95M Buy
16,453
+8,356
+103% +$2.99M 0.02% 482
2020
Q4 		$3.04M Buy
8,097
+3,787
+88% +$1.33M 0.01% 631
2020
Q3 		$1.32M Buy
4,310
+1,651
+62% +$631K 0.01% 797
2020
Q2 		$1M Buy
2,659
+2,625
+7,721% +$743K ﹤0.01% 962
2020
Q1 		$8K Hold
34
– – ﹤0.01% 1714
2019
Q4 		$18K Sell
34
-130
-79% -$70.4K ﹤0.01% 1729
2019
Q3 		$71K Buy
+164
New +$105K ﹤0.01% 1557
2016
Q4 		– Sell
-5
Closed -$4K – 1681
2016
Q3 		$4K Sell
5
-248
-98% -$190K ﹤0.01% 1334
2016
Q2 		$183K Buy
253
+232
+1,105% +$160K ﹤0.01% 946
2016
Q1 		$12K Buy
+21
New +$10.8K ﹤0.01% 1163
2015
Q3 		– Sell
-17
Closed -$14K – 1346
2015
Q2 		$14K Hold
17
– – ﹤0.01% 1114
2015
Q1 		$14K Buy
+17
New +$13.2K ﹤0.01% 1150

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Acadian Asset Management's CBIO Position: Q1 2025 in Review

Acadian Asset Management sold out of Crescent Biopharma (CBIO) in Q1 2025, closing a stake of 11 shares.

Acadian Asset Management first reported a position in CBIO in Q1 2015 and held it in 27 quarters. The position peaked at $5.89M in Q4 2022. 35 funds tracked by Wall St. Rank hold CBIO as of Q1 2025.

  • Acadian Asset Management reported no remaining Crescent Biopharma position as of Q1 2025 after selling out during the quarter.
  • Acadian Asset Management sold 11 Crescent Biopharma shares in Q1 2025.
  • Acadian Asset Management first reported a position in Crescent Biopharma in Q1 2015 and held it in 27 quarters.
  • Acadian Asset Management's Crescent Biopharma position peaked at $5.89M in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.